ArticleCancers2021

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma.

Josep Corominas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.